This opening segment introduces an OncLive program built around ASCO data on risk-guided treatment intensification and sequencing in EGFR-mutated advanced non-small cell lung cancer (NSCLC).
Back
ASCO: Risk-Guided Intensification and Treatment Sequencing in EGFR-Mutated Advanced Non-Small Cell Lung Cancer
Sandip Patel, MD, and Chul Kim, MD, review ASCO data on TP53 co-mutations, the TOP study, frontline therapy selection, and treatment sequencing strategies for patients with EGFR-mutated advanced non-small cell lung cancer.
ASCO: Risk-Guided Intensification and Treatment Sequencing in EGFR-Mutated Advanced Non-Small Cell Lung Cancer
Episodes
All
All
This segment interprets the TOP study findings and their practice implications.
Advertisement
Advertisement
Trending on OncLive
1
FDA Advisory Committee to Weigh RP1 Plus Nivolumab in Anti–PD-1–Pretreated Advanced Melanoma
2
FDA Grants RMAT and Fast Track Designations to Cema-Cel for First-Line LBCL
3
Dr Hashmi on the Identification of Candidates for CAR T-Cell Therapy in Early R/R Myeloma
4
Dr Secord on Combining Mocertatug Rezetecan With Dostarlimab in Endometrial Cancer
5